DFD-29 Extended Release Capsules (40 mg) + DFD-29 Extended Release Capsules (20 mg) + Oraycea® (doxycycline) Capsules + Placebo Capsules
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rosacea
Conditions
Rosacea
Trial Timeline
Oct 1, 2017 → Mar 31, 2019
NCT ID
NCT03340961About DFD-29 Extended Release Capsules (40 mg) + DFD-29 Extended Release Capsules (20 mg) + Oraycea® (doxycycline) Capsules + Placebo Capsules
DFD-29 Extended Release Capsules (40 mg) + DFD-29 Extended Release Capsules (20 mg) + Oraycea® (doxycycline) Capsules + Placebo Capsules is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT03340961. Target conditions include Rosacea.
What happened to similar drugs?
5 of 15 similar drugs in Rosacea were approved
Approved (5) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340961 | Phase 2 | Completed |
Competing Products
20 competing products in Rosacea